For newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations  the standard of care for many years was platinum-doublet chemotherapy Recently  however  immunotherapy with PD-1 inhibitor pembrolizumab  either alone (for patients with PD-L1 expression over 50%) or in combination with platinum-based chemotherapy were approved as new standard for first-line treatment options for nonsquamous and squamous NSCLC